Volume 10 Issue 2
Sep.  2020
Turn off MathJax
Article Contents
Wei HUANG, Zhi-cheng JING. Chronic Thromboembolic Pulmonary Hypertension: Novel Opinion of The 6th World Symposium on Pulmonary Hypertension[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(2): 122-126. doi: 10.3969/j.issn.1674-9081.2019.02.007
Citation: Wei HUANG, Zhi-cheng JING. Chronic Thromboembolic Pulmonary Hypertension: Novel Opinion of The 6th World Symposium on Pulmonary Hypertension[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(2): 122-126. doi: 10.3969/j.issn.1674-9081.2019.02.007

Chronic Thromboembolic Pulmonary Hypertension: Novel Opinion of The 6th World Symposium on Pulmonary Hypertension

doi: 10.3969/j.issn.1674-9081.2019.02.007
More Information
  • Corresponding author: HUANG Wei Tel:023-89011513,E-mail: weihuangcq@gmail.com
  • Received Date: 2018-03-13
  • Publish Date: 2020-09-18
  • The 6th World Symposium on Pulmonary Hypertension was held in Nice between February 28 and March 1, 2018. The major progress in chronic thromboembolic pulmonary hypertension (CTEPH) in the past 5 years was reviewed by the experts of Task Force 11. The definition, classification, pathologic mechanisms, epidemiology, diagnosis, and treatment were updated based on available evidence. Chronic thromboembolic disease (CTED) was defined and the difference between CTED and CTEPH was summarized. All CTEPH patients should be evaluated by a multidisciplinary team. Balloon pulmonary angioplasty (BPA), with improved efficacy and safety, plays an important role in CTEPH therapy. An ongoing study investigates patients with CTEPH who are not eligible for pulmonary endarterectomy and are randomized into medicine therapy or balloon pulmonary angioplasty (BPA), and compares the effects of the two therapies. The combination therapy for CTEPH needs the evidence of a long-term follow-up.
  • loading
  • [1] Quarck R, Wynants M, Verbeken E, et al. Contribution of inflammation and impaired angiogenesis to the pathobiology ofchronic thromboembolic pulmonary hypertension[J]. Eur Respir J, 2015, 46:431-443. doi:  10.1183/09031936.00009914
    [2] Konstantinides SV, Vicaut E, Danays T, et al. Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism[J]. J Am Coll Cardiol, 2017, 69:1536-1544. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=bdea978a70672ee25695ca711b3ce4dc
    [3] Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature[J]. Eur Respir J, 2017, 49:1601792. https://core.ac.uk/display/153431350
    [4] Gopalan D, Blanchard D, Auger WR.Diagnostic Evaluation of Chronic Thromboembolic Pulmonary Hypertension[J]. Ann Am Thorac Soc, 2016, 13:S222-S239. doi:  10.1513/AnnalsATS.201509-623AS
    [5] Delcroix M, Lang I, Pepke-Zaba J, et al. Long-Term Outcome of Patients with Chronic Thromboembolic Pulmonary Hypertension: Results from an International Prospective Registry[J]. Circulation, 2016, 133:859-871. doi:  10.1161/CIRCULATIONAHA.115.016522
    [6] Wiedenroth CB, Olsson KM, Guth S, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease[J]. Pulm Circ, 2018, 8:2045893217753122. https://www.ncbi.nlm.nih.gov/pubmed/25869123
    [7] Aoki T, Sugimura K, Tatebe S, et al. Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: long-term effects and procedure-related complications[J]. Eur Heart J, 2017, 38:3152-3159. doi:  10.1093/eurheartj/ehx530
    [8] Hosokawa K, Abe K, Oi K, et al. Balloon pulmonary angioplasty-related complications and therapeutic strategy in patients with chronic thromboembolic pulmonary hypertension[J]. Int J Cardiol, 2015, 197:224-226. doi:  10.1016/j.ijcard.2015.06.075
    [9] Simonneau G, D'Armini AM, Ghofrani HA, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)[J]. Eur Respir J, 2015, 45:1293-1302. doi:  10.1183/09031936.00087114
    [10] Ghofrani HA, D'Armini AM, Grimminger F, et al. Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension[J]. N Engl J Med, 2013, 369:319-329. doi:  10.1056/NEJMoa1209657
    [11] Ghofrani HA, Simonneau G, D'Armini AM, et al. MERIT study investigators.Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study[J]. Lancet Respir Med, 2017, 5:785-794. doi:  10.1016/S2213-2600(17)30305-3
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(3)

    Article Metrics

    Article views (563) PDF downloads(122) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return